HDL Cholesterol:
Risky study stopped...now what?
New York Times
Expert Summary
With the study of the HDL cholesterol-boosting drug torcetrapib halted due to fatal complications, this article explores the fate of this class of medications.
Margarita Tartakovsky
Expert Scorecard
Overall Expert Score
Community Reviews
Overall Community Rating:
(1 review)
Anonymous
02/21/2008
Is there hope after a failure of a drug during a study? According to this article there is. Torcetrapib seems to be off the market but Merck and Roche are hoping to get their CETP inhibitors approved for use.
Add your rating:
click to select